Physician profile
Avery Scheiner
NPI 1518044965
$11,260.19
in general payments reported to CMS, 2019-2025
32 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $255 · 2021: $2,677 · 2022: $2,723 · 2023: $1,945 · 2024: $1,221 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,158.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,963.11 | 2019-2023 | |
| Abbvie INC. | $2,386.65 | 2019-2025 | Rinvoq, Skyrizi |
| Merz North America, INC. | $1,064.16 | 2019-2023 | |
| Janssen Biotech, INC. | $545.99 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $531.36 | 2019-2025 | |
| Lilly USA, LLC | $413.40 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $384.64 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $322.68 | 2019-2022 | |
| Leo Pharma INC. | $303.40 | 2019-2023 | Adbry |
| Incyte Corporation | $300.68 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $282.49 | 2019-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $246.01 | 2023-2024 | Vtama |
| Ucb, INC. | $234.83 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $201.55 | 2019-2025 | |
| Epi Health, LLC | $196.88 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $125.23 | 2019-2025 | Libtayo |
| Almirall LLC | $117.11 | 2019-2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $97.30 | 2023-2024 | Sotyktu |
| Sebela Pharmaceuticals INC. | $91.38 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $66.56 | 2024-2025 | Zoryve |
| Amgen INC. | $58.93 | 2022-2023 | Otezla |
| Solta Medical, A Division of Bausch Health US, LLC | $42.05 | 2025 | Fraxel |
| Taro Pharmaceuticals USA, INC. | $39.31 | 2019 | |
| Celgene Corporation | $38.81 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.75 | 2019-2020 | |
| Mission Pharmacal Company | $38.67 | 2019-2020 | |
| Nobelpharma America, LLC | $27.31 | 2025 | |
| Aclaris Therapeutics, INC. | $23.44 | 2019 | |
| Mayne Pharma Commercial LLC | $20.17 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $20.11 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.86 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Scheiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.